Complete Guide to IMHA Diagnosis in Dogs

Immune-mediated hemolytic anemia (IMHA) is one of the most common immune-mediated diseases in dogs, accounting for up to 75% of immune-mediated blood disorders. Early recognition and appropriate treatment are critical for patient survival.

Pathophysiology

IMHA occurs when antibodies are directed against red blood cell surface antigens, leading to extravascular hemolysis (primarily in the spleen and liver) or intravascular hemolysis. The resulting anemia can be life-threatening when the bone marrow cannot compensate rapidly enough.

## Clinical Presentation

Dogs with IMHA typically present with:

Acute lethargy and weakness — Often the first sign owners notice
- Pale mucous membranes — Due to severe anemia
- Tachycardia — Compensatory response to decreased oxygen delivery
- Icterus — When hemolysis exceeds the liver's conjugation capacity
- Fever — Due to inflammatory mediators
- Petechiae/ecchymoses — If concurrent IMT (Evans syndrome)

## Diagnostic Approach

First-Line Tests
1. CBC with reticulocyte count — Confirms anemia and assesses regenerative response
2. Blood smear evaluation — Look for spherocytosis, polychromasia, autoagglutination
3. Coombs test (DAT) — Confirms immune-mediated mechanism (sensitivity 60-90%)

### Second-Line Tests
- Tick-borne disease panel (Babesia, Ehrlichia, Anaplasma)
- Abdominal ultrasound (rule out hemangiosarcoma)
- Thoracic radiographs (rule out neoplasia)
- Coagulation profile (rule out DIC)
- Serum biochemistry (assess organ function)

## Treatment Principles

### Immunosuppression
- Prednisone: 2 mg/kg/day initially, taper over 3-6 months
- Azathioprine: 2 mg/kg/day (dogs only — toxic to cats)
- Mycophenolate: 10 mg/kg BID as alternative steroid-sparing agent

### Supportive Care
- Transfusion: Consider when PCV <15% or patient is hemodynamically unstable
- Gastroprotection: Omeprazole 1 mg/kg/day
- Thromboprophylaxis: Clopidogrel 2-5 mg/kg/day (IMHA patients are hypercoagulable)

## Prognosis

With appropriate treatment, survival rates range from 50-80%. Poor prognostic indicators include:
- Severe thrombocytopenia (Evans syndrome)
- Intravascular hemolysis
- Organ failure at presentation
- Need for multiple transfusions

## Key Takeaways

IMHA is a diagnosis that requires rapid recognition and aggressive treatment. The combination of compatible clinical signs, laboratory evidence of hemolysis, and a positive Coombs test confirms the diagnosis. Early immunosuppression and thromboprophylaxis are the cornerstones of successful management.